Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2001
10/18/2001CA2405779A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001CA2405730A1 Serine-threonine kinase
10/18/2001CA2405568A1 Prion-binding peptidic ligands and methods of using same
10/18/2001CA2405561A1 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
10/18/2001CA2405554A1 Intracorporeal medicaments comprising halogenated xanthenes for high energy phototherapeutic treatment of disease
10/18/2001CA2405476A1 Compounds and methods for modulating endothelial cell adhesion
10/18/2001CA2405425A1 Dermatological preparations containing thyronine derivatives and uses thereof
10/18/2001CA2405419A1 Apomorphine derivatives and methods for their use
10/18/2001CA2405411A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001CA2405306A1 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001CA2405181A1 Human pyruvate dehydrogenese phosphatase
10/18/2001CA2405163A1 Soluble beta amyloid precursor protein secretion promoters
10/18/2001CA2405151A1 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001CA2405142A1 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
10/18/2001CA2405117A1 Specific inhibitors of ribosome recycling factor (rrf)
10/18/2001CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001CA2405066A1 Percyquinnin, a process for its production and its use as a pharmaceutical
10/18/2001CA2405004A1 Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
10/18/2001CA2404994A1 Pyrazolo-triazine derivatives as ligands for gaba receptors
10/18/2001CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001CA2404630A1 Cathepsin cysteine protease inhibitors
10/18/2001CA2404273A1 Substituted lactams as inhibitors of a.beta. protein production
10/18/2001CA2404229A1 Human transporters and ion channels
10/18/2001CA2404087A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001CA2403365A1 Quinazoline compounds
10/18/2001CA2403144A1 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001CA2403140A1 Novel chromosomal vectors and uses thereof
10/18/2001CA2403012A1 Chemical compounds
10/18/2001CA2402410A1 The high bone mass gene of 11q13.3
10/18/2001CA2401836A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/17/2001EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001EP1146050A1 Remedies
10/17/2001EP1145717A2 Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor
10/17/2001EP1145713A1 Telomerase inhibitors
10/17/2001EP1145711A1 Flash-melt oral dosage formulation
10/17/2001EP1145710A1 Use of ascorbic acid derivatives for increasing epidermal ceramides synthesis
10/17/2001EP1145705A2 Composition, especially a cosmetic composition, containing a steroid and a 2-alkyl alkanol or ester thereof
10/17/2001EP1145644A2 Glycoprotein having inhibitory activity against helicobacter pylori colonization
10/17/2001EP1145001A2 (in vitro) model for gastrointestinal inflammation
10/17/2001EP1144671A2 Enriched central nervous system cell populations
10/17/2001EP1144634A2 Novel complex-forming proteins
10/17/2001EP1144633A1 Polypeptide
10/17/2001EP1144630A2 Human cell signaling proteins (csig)
10/17/2001EP1144625A2 Nucleic-acid binding proteins
10/17/2001EP1144614A2 33 human secreted proteins
10/17/2001EP1144613A1 Methods for making proteins containing free cysteine residues
10/17/2001EP1144609A2 Chimeric antisense oligonucleotides and cell transfecting formulations thereof
10/17/2001EP1144600A2 Akt-3 nucleic acids, polypeptides, and uses thereof
10/17/2001EP1144592A2 Substrate for cell growth
10/17/2001EP1144454A2 Modified peptides as therapeutic agents
10/17/2001EP1144453A1 Anti-ccr4 antibodies and methods of use therefor
10/17/2001EP1144450A1 Mammalian alpha-helical protein - 12
10/17/2001EP1144446A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
10/17/2001EP1144426A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
10/17/2001EP1144425A1 Derivatives of monosaccharides as cell adhesion inhibitors
10/17/2001EP1144421A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases
10/17/2001EP1144413A1 2,5-diazabicyclo 2.2.1]heptane derivatives, their preparation and therapeutic uses
10/17/2001EP1144411A1 Antihistaminic spiro compounds
10/17/2001EP1144410A2 Use of imidazo 1,5-a]-pyrido 3,2-e]-pyrazinones as medicaments
10/17/2001EP1144409A2 Phenyl urea and phenyl thiourea derivatives
10/17/2001EP1144405A1 Triazole compounds with dopamine-d3-receptor affinity
10/17/2001EP1144403A1 Substitued pyrazoles as p38 kinase inhibitors
10/17/2001EP1144402A2 Substituted oximes and hydrazones as neurokinin antagonists
10/17/2001EP1144395A1 2-amino-benzoxazinone derivatives for the treatment of obesity
10/17/2001EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor
10/17/2001EP1144390A2 Kinase inhibitors
10/17/2001EP1144389A1 Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoicacid]calcium salt
10/17/2001EP1144388A1 Acyl derivatives which treat vla-4 related disorders
10/17/2001EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
10/17/2001EP1144386A1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
10/17/2001EP1144385A1 Benzoheterocycles and their use as mek inhibitors
10/17/2001EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001EP1144377A1 Oxetanone derivatives
10/17/2001EP1144371A1 Benzenesulphonamide derivatives and their use as mek inhibitors
10/17/2001EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/17/2001EP1144368A2 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
10/17/2001EP1144362A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
10/17/2001EP1144348A2 Lta 4? hydrolase inhibitors
10/17/2001EP1144305A1 NOVEL sPLA 2 INHIBITORS
10/17/2001EP1144050A2 Binding partners for 5-ht5-receptors for the treatment of migraine
10/17/2001EP1144003A1 Methods and devices for delivery of agents to breast milk ducts
10/17/2001EP1143999A2 Lipoprotein complexes and compositions containing them
10/17/2001EP1143998A2 Treatment of hypertension
10/17/2001EP1143994A2 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
10/17/2001EP1143991A2 Inhibitors of h+k+ -atpase
10/17/2001EP1143987A1 Natural composition and method for the treatment of sexual dysfunction
10/17/2001EP1143985A2 Use of lactobacillus salivarius
10/17/2001EP1143981A1 Treatment and prevention of hiv and other viral infections
10/17/2001EP1143979A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes
10/17/2001EP1143977A1 2-oxy-benzoxazinone derivatives for the treatment of obesity
10/17/2001EP1143973A2 Compositions having improved stability
10/17/2001EP1143965A1 Carbocyclic potassium channel inhibitors
10/17/2001EP1143964A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
10/17/2001EP1143961A2 Regulators of the ptc or smoothened pathway, compositions and uses related thereto
10/17/2001EP1143960A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
10/17/2001EP1143957A2 Treatment of arthritis with mek inhibitors
10/17/2001EP1143956A2 Compositions and methods for the treatment of anorectal disorders
10/17/2001EP1143948A2 Liver-selective glucocorticoid antagonist for treating diabetes
10/17/2001EP1143945A2 Carnitine supplemented diet to prevent sudden death syndrome in broiler breeder type poultry
1 ... 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 ... 1564